Bethesda, Md. – AABB is pleased to announce that Miriam A. Markowitz has joined the association as chief executive officer.
"Miriam Markowitz is an accomplished professional with years of solid experience running and managing organizations and steering them through change," said AABB President Susan L. Stramer, PhD. "She has a personal and professional passion for the scope of AABB's work in transfusion medicine and cellular therapies and is committed to advancing our mission of optimizing patient and donor care and safety."
As CEO, Markowitz is responsible for providing the overall leadership and direction to this $25 million organization and its staff of approximately 100 to ensure effective administration of association policies, programs and activities as set in cooperation and consultation with the volunteer leadership of AABB.
Prior to joining AABB, Markowitz was chief operating officer at Georgetown University Medical Center — or GUMC — an academic medical center with a three-part mission of research, teaching and service. In this role, she served as strategy advisor and supported relationship development with outside organizations regarding program development, public-private partnerships, and regulatory and policy-making issues. Prior to joining GUMC in 2011, Markowitz served as corporate vice president of strategy and business development at Children's National Medical Center. Markowitz received a Bachelor of Arts degree in economics from Brandeis University and a Master of Science degree in health policy and management from Harvard School of Public Health.
Markowitz serves on the board of directors for the National Marrow Donor Program as vice chair. She is an adjunct professor at Georgetown University, teaching strategic planning and business planning and development within the Master of Science in Health Systems Administration program. She also recently completed two terms as mayoral appointee to the District of Columbia Board of Medicine, serving as consumer member.
"Addressing the needs of the transfusion medicine and cellular therapy community fascinates me both intellectually and managerially," said Markowitz. "I am excited to focus deeply on the subject matter and work with a terrific set of experts — including members, professional volunteers and employees who drive and shape the field."
Markowitz was recruited by the AABB Board of Directors after a thorough and deliberate nationwide search, taking office on May 20. She replaces Karen L. Shoos, JD, who retired as CEO after serving in this position for 19 years.
AABB is an international, not-for-profit association representing individuals and institutions involved in the field of transfusion medicine and cellular therapies. The association is committed to improving health by developing and delivering standards, accreditation and educational programs that focus on optimizing patient and donor care and safety. AABB membership consists of nearly 2,000 institutions and 8,000 individuals, including physicians, nurses, scientists, researchers, administrators, medical technologists and other health care providers. Members are located in more than 80 countries. For more information, visit www.aabb.org.